MET外显子14改变及酪氨酸激酶抑制剂新耐药突变:当前基于扩增子的NGS panel检测不足的风险
研究评估八种基于扩增子的二代测序panel检测MET外显子14改变及ALK、ROS1、EGFR耐药突变的能力。对191例非小细胞肺癌样本行Sanger测序筛查METex14,另62例用Sanger测序和两个扩增子panel筛查。阳性病例NGS分析发现一例因扩增子设计导致的假阴性;计算机模拟分析显示八种panel均无法检出超过63%的文献报道METex14突变,对新耐药突变存在类似局限。
要点
- 八种基于扩增子的NGS panel均无法检出超过63%的文献报道METex14突变。
- 阳性METex14病例NGS分析发现一例因扩增子设计导致的假阴性。
- 对ALK、ROS1、EGFR新耐药突变预期存在类似检测局限。
核心结论
- 商用基于扩增子的DNA NGS panel在检测METex14及新报道的TKI耐药突变方面存在重大局限。
- 记录所选可用panel并频繁重新评估对向临床医生提供最准确数据以做出治疗决策是必需的。
研究设计与样本
- 对191例非小细胞肺癌患者肿瘤样本用Sanger测序筛查METex14突变。
- 另62例用Sanger测序和两个基于扩增子的NGS panel筛查。
- 对八种商用靶向NGS panel检测METex14改变或ALK、ROS1、EGFR耐药突变进行计算机模拟比较。
主要发现
- 阳性METex14病例的NGS分析发现一例因扩增子设计导致的假阴性。
- 计算机模拟分析显示八种panel中无一能检出超过63%的文献报道METex14突变。
- 对新ALK、ROS1或EGFR耐药突变预期存在类似局限。
关键数值与推荐
- 八种panel均无法检出超过63%的文献报道METex14突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Targeted therapies such as tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment of lung adenocarcinoma, and detection of activating mutations of genes such as EGFR or anaplastic lymphoma kinase gene (ALK) is now mandatory in the clinical setting. However, additional targetable alterations are continuously being described and forcing us to adapt our detection methods. Here we have evaluated the ability of eight amplicon-based next-generation sequencing (NGS) panels to detect the recently described mesenchymal epithelial transition factor (MET) exon 14 (METex14) alterations or new mutations conferring resistance to TKIs. METHODS: A total of 191 tumor samples from patients with NSCLC were screened for METex14 mutations by Sanger sequencing, and 62 additional cases were screened by Sanger sequencing and two amplicon-based NGS panels. In silico comparison of eight commercially available targeted NGS panels was also performed for the detection of METex14 alterations or ALK, ROS1, or EGFR resistance mutations. RESULTS: NGS analysis of the positive METex14 cases revealed a false-negative case because of amplicon design. Moreover, in silico analysis revealed that none of the eight panels considered would be able to detect more than 63% of literature-reported cases of METex14 mutations and similar limitations would be expected with new ALK, ROS1, or EGFR resistance mutations. CONCLUSIONS: We have illustrated major limitations of commercially available amplicon-based DNA NGS panels for detection of METex14 and recently described resistance mutations to TKIs. Documented choice of available panels and their frequent reevaluation are mandatory to deliver the most accurate data to the clinician for therapeutic decisions.
引用
- Poirot B, Doucet L, Benhenda S, et al. MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels. J Thorac Oncol. 2017. PMID: 28779874. doi:10.1016/j.jtho.2017.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。